Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey W Clark

Showing results (11-20 of 210) with videos related to

Pageof 21
Sort By:
Surgical Oncology Clinics of North America|September 8, 2004
Adjuvant therapy for pancreatic cancer: an evolving paradigmAndrew X Zhu, Jeffrey W Clark, Christopher G Willett
Cancer Discovery|May 16, 2012
Cancers of the colon and rectum: identical or fraternal twins?Theodore S Hong, Jeffrey W Clark, Kevin M Haigis
Lung Cancer (Auckland, N.Z.)|February 18, 2017
Targeted inhibition in tumors with ALK dependencyEunice L Kwak, Jeffrey W Clark, Alice T Shaw
The Lancet. Oncology|April 8, 2018
Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target?Colin D Weekes, Jeffrey W Clark, Andrew X Zhu
The New England Journal of Medicine|June 11, 2004
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 18-2004. A 61-year-old man with rectal bleeding and a 2-cm mass in the rectumPaul C Shellito, Jeffrey W Clark, Christopher G Willett, et al.
Journal of the National Cancer Institute|June 26, 2014
Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experienceSuzanne E Dahlberg, Geoffrey I Shapiro, Jeffrey W Clark, et al.
Seminars in Oncology|August 9, 2003
Combined modality therapy for rectal and colon cancerAshish K Chawla, Lisa A Kachnic, Jeffrey W Clark, et al.
Nature Clinical Practice. Oncology|January 13, 2006
Lessons from phase III clinical trials on anti-VEGF therapy for cancerRakesh K Jain, Dan G Duda, Jeffrey W Clark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumorsJeffrey W Clark, Joseph P Eder, David Ryan, et al.
The New England Journal of Medicine|October 18, 2018
Case 32-2018: A 36-Year-Old Pregnant Woman with Newly Diagnosed AdenocarcinomaJanet E Murphy, Kimberly Shampain, Laura E Riley, et al.
Pageof 21

Showing results (11-20 of 210) with videos related to

Sort By:
Pageof 21
Surgical Oncology Clinics of North America|September 8, 2004
Adjuvant therapy for pancreatic cancer: an evolving paradigmAndrew X Zhu, Jeffrey W Clark, Christopher G Willett
Cancer Discovery|May 16, 2012
Cancers of the colon and rectum: identical or fraternal twins?Theodore S Hong, Jeffrey W Clark, Kevin M Haigis
Lung Cancer (Auckland, N.Z.)|February 18, 2017
Targeted inhibition in tumors with ALK dependencyEunice L Kwak, Jeffrey W Clark, Alice T Shaw
The Lancet. Oncology|April 8, 2018
Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target?Colin D Weekes, Jeffrey W Clark, Andrew X Zhu
The New England Journal of Medicine|June 11, 2004
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 18-2004. A 61-year-old man with rectal bleeding and a 2-cm mass in the rectumPaul C Shellito, Jeffrey W Clark, Christopher G Willett, et al.
Journal of the National Cancer Institute|June 26, 2014
Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experienceSuzanne E Dahlberg, Geoffrey I Shapiro, Jeffrey W Clark, et al.
Seminars in Oncology|August 9, 2003
Combined modality therapy for rectal and colon cancerAshish K Chawla, Lisa A Kachnic, Jeffrey W Clark, et al.
Nature Clinical Practice. Oncology|January 13, 2006
Lessons from phase III clinical trials on anti-VEGF therapy for cancerRakesh K Jain, Dan G Duda, Jeffrey W Clark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumorsJeffrey W Clark, Joseph P Eder, David Ryan, et al.
The New England Journal of Medicine|October 18, 2018
Case 32-2018: A 36-Year-Old Pregnant Woman with Newly Diagnosed AdenocarcinomaJanet E Murphy, Kimberly Shampain, Laura E Riley, et al.
Pageof 21